TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: STI infection rates among PrEP user
Endpoint domain: Adverse events/effects
Primary endpoint: Change in baseline fecal bifidobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in the PCS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical Response to CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in post restorative soft tissue height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Action Defined as the Time With Urine Osmolality Above 200 mOsm/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Number of Nocturnal Voids After 28 Days of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of HPV subtypes associated with cervical cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: acute changes in Left-ventricular ejection fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiac inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiac perfusion changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dual-task walking performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy status at 20 weeks of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Morning (AM) Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Rate of Cardiovascular Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Heart Failure Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major Adverse Neurological and Cardiovascular Events (MANCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Amino-terminal prohormone of brain natriuretic peptide (NT-proBNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Six Minute Hall Walk (6MHW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Minnesota Living With Heart Failure Quality of Life (MLWHF QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Blood plasma alpha linolenic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Unified Parkinson's disease rating scale (UPDRS) part III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Foetal macrosomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Improvement in overall opportunity-based composite measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Whole Blood Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Systolic Blood Pressure (SBP) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Diastolic Blood Pressure (DBP) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Classified as a 'Clinical Success'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean transit time of the time intensity curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Intensity of the time intensity curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Are under the curve of the time intensity curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient Hyperemic response test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean velocity of the middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of Subjects With Progressive Respiratory Insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of hookworm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Molecular Breast Imaging (MBI) scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total number of blisters from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Modified ABSIS score change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of patients completely free from blisters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Blood Pressure and Heart Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma Biomarkers of Coagulation and Fibrinolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients Who Got New Brain Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Take-home baby
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of emergency general surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: satisfactory hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom from MRI-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of successful spinal needle placement in the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: The number of needle-bone contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Reading Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in canine retraction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Walked on a Treadmill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Maximum Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Half-life (t½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in mean HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in mean visual analogue scores (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of SAEs to Day 84
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of related SAEs to Day 84
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of any solicited or unsolicited Grade 3 or Grade 4 events up to Day 84
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in 24-hours mean systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in perception of asthma self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Forced Vital Capacity (FVC) Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change on attention test, TMTB-TMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of cancer formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence or absence of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma atorvastatin concentration (AUClast, AUCinf, Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Movement Screen (FMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic Measurement of Knee Muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: occlusal force distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Nicotine Concentration-Time Curve (AUC(0-last))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ABPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uptake of screening for LTBI in antenatal care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Offer of IGRA blood test screening by healthcare providers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of Hepatic Venous Pressure Gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Lesion size (main diameter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumoral response determined by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influenza immunisation uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overdose Risk Behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overdose Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Behavioral Intentions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Penile microvascular vasodilatory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from baseline Active Engagement at month 6
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from baseline Loneliness at month 6
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effective treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytotoxicity and genotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Bowl Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in the Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Episodes of self-reported nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Episodes of self-reported vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical performance of autoantibody panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Status of diagnosis of postoperative delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain scores during intrauterine device insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment effectiveness for Vulvovaginal Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mutation rate on tumorous material
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of non transplantable recurrence
Endpoint domain: Mortality/survival
Primary endpoint: safety of PEG-BCT-100
Endpoint domain: Adverse events/effects
Primary endpoint: area under the curve of plasma drug concentration (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects reaching target BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of subjects reaching target LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Delta in the number of patients requiring orotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Progression-free survival at 4.5 months
Endpoint domain: Mortality/survival
Primary endpoint: Skin tolerance (redness or itchiness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Moisturizing level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Elasticity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: cardiovascular hospitalization: cardiac decompensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Erythema as measured by Laser Doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Heat pain threshold (deg C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesia to temporal summation of heat pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Post-baseline Clinically Significant Findings in Physical Examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Rivipansel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speckle tracking strain measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Preinterventional Scores on the W-DEQ-A
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VAS scores of the experimental and control groups
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BSS-R scores of experimental and control groups
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in thickness of the vaginal epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Acute Kidney Injury reversal by day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: DVT or PE incidence
Endpoint domain: Mortality/survival
Primary endpoint: Health Related Quality of Life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 28-day progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Time Taken to Complete the Procedure of Awake Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Renal function (serum creatinine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Symptom Severity Burden
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Twenty-four hour urinary Na/K ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Variation of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Without Relapse
Endpoint domain: Mortality/survival
Primary endpoint: COPD assessment test (CAT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: St. George's respiratory questionnaire (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modified medical research council (mMRC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of lungs meeting eligibility criteria for transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resiliency
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stress Reactivity/Coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of negative breath samples submitted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delivery time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Treatment-emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Moderate and Severe AECOPD (Any Cause)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lateral spread response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in microbiome species abundance and diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of large genital warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: % weight decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Two-year progression free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Corneal Nerve Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin D Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of emotional stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Extent of inter-fractional and intra-fractional movement of the GTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute and long-term toxicity of pre-operative radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in EORTC QLQ-C30 scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of complete (100%) wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants achieving hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Key Pinch Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tip Pinch Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerated dose of NVX-508
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotenoid levels in blood and prostate tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of HIV
Endpoint domain: Mortality/survival
Primary endpoint: Change in copeptin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development or worsening of a ventilatory disorder and/or chronic respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Electroretingraphy Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffusion of dolutegravir in sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Diffusion of dolutegravir in lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diffusion of dolutegravir in fat tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diffusion of dolutegravir in rectal tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants with New Onset Systemic Inflammatory Response Syndrome (SIRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Wellens Sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood brain barrier permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Lichen sclerosus score (LS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Middle term failure
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of AEs resulting in study discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced size of the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Growth faltering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Purity after isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum and urinary metabolites of reproductive hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Urinary metabolites of endocrine disrupting chemicals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes